Kanamycin-Pos

Kanamycin Monosulphate, the active ingredient in Kanamycin-Pos, is an aminoglycoside antibiotic presented as a sterile ophthalmic preparation for ocular use. It treats bacterial eye infections such as conjunctivitis and keratitis in patients requiring topical therapy. The product complies with European Union pharmacopeial specifications and is manufactured under GMP conditions.

GNH USA supplies Kanamycin-Pos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Kanamycin-Pos is used in ophthalmology to treat bacterial infections of the eye surface and cornea. - Bacterial conjunctivitis: reduces bacterial load and alleviates redness and discharge. - Corneal ulcer (bacterial keratitis): promotes healing by eradicating causative organisms. - Post‑operative prophylaxis: prevents bacterial contamination after ocular surgery. - Trachoma or other bacterial conjunctival infections: controls infection and limits spread.

Kanamycin‑Pos may cause local and systemic adverse reactions, most of which are related to its aminoglycoside class.

Common Side Effects: - Eye irritation: mild burning or stinging upon instillation. - Redness: transient conjunctival hyperemia. - Tearing: increased lacrimation. - Blurred vision: temporary visual disturbance. - Itching: mild pruritus of the ocular surface. - Photophobia: sensitivity to light.

Serious or Rare Side Effects: - Corneal epithelial toxicity: ulceration or delayed healing. - Allergic reaction: swelling, rash, or eosinophilic conjunctivitis. - Systemic ototoxicity: hearing impairment if significant absorption occurs. - Nephrotoxicity: renal function impairment in susceptible patients. - Anaphylaxis: severe, life‑threatening hypersensitivity. - Stevens‑Johnson syndrome: rare mucocutaneous eruption.

Before using Kanamycin‑Pos, clinicians should consider several safety precautions to minimize risks. - Hypersensitivity: confirm no known allergy to kanamycin or other aminoglycosides. - Infection type: avoid use in viral, fungal or allergic conjunctivitis. - Renal function: assess renal status in patients at risk of systemic absorption. - Contact lens wear: discontinue lenses during treatment to reduce irritation. - Duration of therapy: limit use to the shortest effective period to prevent toxicity. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Kanamycin‑Pos can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., vancomycin, amphotericin B): increase risk of renal damage. - Ototoxic drugs (e.g., loop diuretics, cisplatin): potentiate hearing loss. - Neuromuscular blockers (e.g., succinylcholine): may enhance muscle weakness.

Moderate Interactions (Monitor Closely): - Other topical antibiotics: risk of additive toxicity or antagonism. - Topical anesthetics: may increase corneal irritation. - Systemic aminoglycosides: cumulative exposure may raise systemic toxicity.